BioMarin Deal History & Licensing Activity
BioMarin is a large biotech headquartered in US. Over the past three years, BioMarin has been involved in 5 licensing and acquisition transactions, with a primary focus on Peptides (2 deals). The company currently has 37 active clinical trials, primarily in Rare Disease.
Deals (12mo)
4
Active Trials
37
Top Modality
Peptides
Focus Area
Rare Disease
BioMarin Recent Deal Activity
Licensing, acquisition, and partnership transactions involving BioMarin in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Yuviwel | Ascendis Pharma A/S | Peptides | Approved | license | Aug 31, 2026 |
| ALE1 | BioMarin Pharmaceutical | Small Molecules | Phase 1 | acquisition | Aug 18, 2026 |
| antisense oligonucleotide for ReNU syndrome | BioMarin Pharmaceutical Inc. | Oligonucleotides | Preclinical | collaboration | Jul 27, 2026 |
| Amicus Therapeutics (full company acquisition; includes Galafold and pipeline) | BioMarin Pharmaceutical | Small Molecules | Approved | acquisition | Dec 19, 2025 |
BioMarin Pipeline Focus
Therapeutic areas and modalities where BioMarin is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
BioMarin Strategic Signals
Key indicators of BioMarin's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
BioMarin Clinical Pipeline
BioMarin has 37 active clinical trials across 7 development phases.
1
Phase 4
11
Unknown
2
Phase 1
4
Phase 1/2
8
Phase 2
3
Phase 2/3
8
Phase 3
See How Your Asset Matches BioMarin's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Peptides Benchmarks
Upfront, milestone, and royalty benchmarks for peptides deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About BioMarin Licensing & Deal Activity
BioMarin is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, BioMarin ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for BioMarin include Rare Disease (14 deals and trials), Rare Disease (9 deals and trials), Musculoskeletal (9 deals and trials), and Autoimmune (1 deal and trial). In terms of modality, BioMarin has shown particular interest in peptides, small molecules, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for BioMarin and 700+ other biopharma companies. Use our Solidus to benchmark your asset against BioMarin's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.